<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951079</url>
  </required_header>
  <id_info>
    <org_study_id>MMC130077-12CTIL</org_study_id>
    <nct_id>NCT01951079</nct_id>
  </id_info>
  <brief_title>Intra Amniotic Injection of DIGOXIN for Feticide in Second Trimester Termination of Pregnancy</brief_title>
  <official_title>The Safety and Outcome of Intra-amniotic DIGOXIN Injection for Feticide Prior to Second Trimester Abortion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In second trimester abortion above 22 weeks the investigators usually inject intra-cardiac
      Kcl for feticide. Digoxin intra-amniotic injection has been described in the literature in
      doses of 1-1.5 mg. with a success rate of about 80%, and up to 24 weeks. Our aim in this
      study is to investigate the safety and success rate of 1.5-2 mg. digoxin, intra-amniotic up
      to 30 weeks pregnancy .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The digoxin will be injected intra-amniotic with U.S guided, trying to avoid any
           placental passage or intravascular injection /

        -  Any patient will have prior to the procedure a full examination including E.C.G and
           cardiac clearance.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficiency of intra-amniotic Digoxin injection for second trimester feticide</measure>
    <time_frame>a year</time_frame>
    <description>To measure the Success rate of intra-amniotic Digoxin injection for feticide prior to second trimester abortion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Arrhythmia</condition>
  <condition>ECG Changes</condition>
  <condition>Hypotension</condition>
  <arm_group>
    <arm_group_label>second trimester abortion , feticide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patients admitting to second trimester abortion above 22 weeks will be injected intra-amniotic DIGOXIN for feticide .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-amniotic injection of DIGOXIN</intervention_name>
    <arm_group_label>second trimester abortion , feticide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy women with no medical, cardiac, hypertension, liver or renal problems -
             pregnant in their 20-30 week gestation,

          -  that need to have abortion due to fetal anomalies or any other reason

          -  need to have feticide prior to the procedure

        Exclusion Criteria:

          -  any patient with medical problem that may be a contra-indication to Digoxin

          -  cardiac problems,

          -  prior cardiac surgery,

          -  liver or kidney disease,

          -  hyper tension etc.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zvi Klein, M.D</last_name>
    <phone>972-9-7472544</phone>
    <email>kleinz@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regina agizim, M.D.</last_name>
    <phone>972-9-7472561</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. Zvi Klein</name>
      <address>
        <city>Kefar-saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapir medical center</name>
      <address>
        <city>Kefar-saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digoxin</keyword>
  <keyword>Intra-amniotic injection</keyword>
  <keyword>feticide</keyword>
  <keyword>second trimester abortion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

